

Respiratory manifestations of hypothyroidism

A systematic review

Sorensen, Jesper Roed; Winther, Kristian Hillert; Bonnema, Steen Joop; Godballe, Christian; Hegedus, Laszlo

Published in:
Thyroid

DOI:
10.1089/thy.2015.0642

Publication date:
2016

Document version:
Accepted manuscript

Citation for pulished version (APA):

Sorensen, J. R., Winther, K. H., Bonnema, S. J., Godballe, C., & Hegedus, L. (2016). Respiratory manifestations of hypothyroidism: A systematic review. *Thyroid*, 26(11), 1519-1527. <https://doi.org/10.1089/thy.2015.0642>

Go to publication entry in University of Southern Denmark's Research Portal

Terms of use

This work is brought to you by the University of Southern Denmark.
Unless otherwise specified it has been shared according to the terms for self-archiving.
If no other license is stated, these terms apply:

- You may download this work for personal use only.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying this open access version

If you believe that this document breaches copyright please contact us providing details and we will investigate your claim.
Please direct all enquiries to puresupport@bib.sdu.dk

Respiratory manifestations of hypothyroidism
- A systematic review

Jesper Roed Sorensen¹, MD; jesper.roed.sorensen@rsyd.dk

Kristian Hillert Winther², MD; kristian.winther@rsyd.dk

Steen Joop Bonnema², DMSc; steen.bonnema@dadlnet.dk

Christian Godballe¹, PhD; christian.godballe@rsyd.dk

Laszlo Hegedüs², DMSc; laszlo.hegedus@rsyd.dk

1) Department of ORL - Head & Neck Surgery

2) Department of Endocrinology

Odense University Hospital, Sdr. Boulevard 29, 5000 Odense C, Denmark

Word count: 3.062

Figures: 1

Tables: 3

References: 66

33 **Abstract**

34 Background: Hypothyroidism has been associated with increased pulmonary morbidity and overall
35 mortality. We conducted a systematic review to identify the prevalence and underlying mechanisms
36 of respiratory problems among patients with thyroid insufficiency.

37
38 Methods: PubMed and EMBASE databases were searched for relevant literature from January 1950
39 through January 2015 with study eligibility criteria: English-language publications; Adult
40 subclinical or overt hypothyroid patients; Intervention, observational or retrospective studies;
41 and respiratory manifestations. We followed the PRISMA statement and used the Cochrane’s risk
42 of bias tool.

43
44 Results: A total of 1699 papers were screened by two independent authors for relevant titles. Of 109
45 relevant abstracts, 28 papers underwent full text analyses, of which 22 were included in the review.
46 We identified possible mechanisms explaining respiratory problems at multiple physiological
47 levels such as the ventilator control system, diaphragmatic muscle function, pulmonary gas
48 exchange, goiter caused upper airway obstruction, decreased capacity for energy transduction, and
49 reduced glycolytic activity.

50 Obstructive sleep apnea syndrome was found among 30% of newly diagnosed patients with overt
51 hypothyroidism, and demonstrated reversibility following treatment. The evidence for or against a
52 direct effect on pulmonary function was ambiguous. However, each of the above mentioned areas
53 were only dealt with in a limited number of studies.

54 Therefore, we refrain from giving strong conclusions on any of these themes. Moreover, most
55 studies were hampered by considerable risk of bias due to e.g. small numbers of patients, lack of
56 control groups, randomization and blinding, and differences in BMI, gender, and age

57 between subjects and controls.

58

59 Conclusion: Mechanistic data, linking hypothyroidism and respiratory function are at best limited.

60 This area of research is therefore open for retesting hypotheses, using appropriate study designs and
61 methods.

62 Systematic review registration number on PROSPERO: CRD42015016815.

63

64

65 **Introduction**

66 Overt hypothyroidism is a common endocrine condition, which affects 1-2% of adults
67 (1), while subclinical hypothyroidism has been reported in 4-20% (2). It is most often caused by
68 autoimmunity, but may also be a consequence of radioiodine treatment or thyroid surgery as the
69 most prominent other causes (3-5). Hypothyroidism may give rise to many physical (6) and mental
70 symptoms (6, 7) and is associated with increased mortality (8). The increased mortality might, at
71 least partly, be explained by increased pre-existing pulmonary morbidity, or excess pulmonary co-
72 morbidity after the diagnosis of hypothyroidism (8, 9). In the extremely rare but potentially deadly
73 case of myxedema coma, the severe thyroid failure has a direct effect on the respiratory function via
74 the ventilator control system (carotid glomus and brain stem respiratory centers) (10, 11). Upper
75 airway obstruction (UAO) may also contribute to the pulmonary morbidity, either by the presence
76 of a goiter in classical Hashimoto's thyroiditis or from macroglossia, thickening of vocal cords, and
77 mucopolysaccharide deposits in the respiratory tract, as observed in patients with severe myxedema
78 (11-13). However, several other factors probably contribute to the link between hypothyroidism, the
79 respiratory system, and increased mortality.

80 Here, based on the observed increased mortality and pulmonary co-morbidity, we aim
81 at investigating – by a literature review - the impact of hypothyroidism on pulmonary function and
82 the respiratory system, an issue very sparsely addressed previously.

83

84 **Methods**

85 We performed a systematic review according to the Preferred Reporting Items for
86 Systematic reviews and Meta-Analyses (PRISMA) statement (14). Methods as well as inclusion and
87 exclusion criteria were specified in advance in a review protocol, which can be accessed at
88 <http://www.crd.york.ac.uk/PROSPERO/> by registration no. CRD42015016815.

English-language publications on the relationship between respiratory function and hypothyroidism, accessible in PubMed and EMBASE databases (January 1 1950 – January 31 2015), were identified. We used the PICOS approach (Population, Intervention, Comparison, Outcome and Study design) for setting the research question (15). All studies dealing with overt or subclinical hypothyroid patients were considered if the outcome was related to the respiratory function. Both observational and interventional studies were accepted, irrespective of whether the design was retrospective, cross sectional, or prospective. No comparator group was necessary. We performed the last search on February 20, 2015. The full search strategy is provided in the appendix.

Literature search

Two authors (JS and KW) independently screened the titles and abstracts. They decided, by consensus, which articles to evaluate in full text. We searched for outcomes related to neurological ventilatory control, pulmonary gas exchange, pulmonary function, respiratory strength, and sleep apnea. Only English language articles were included. The exclusion criteria were: case reports, expert opinions, letters, reviews, and studies conducted in pregnant patients or those with thyroid cancer. Multiple reports of the same set of data were assessed, and only the most representative or updated report was included. We screened the reference lists of included full text articles for missing publications. The same two authors extracted data independently, according to a pre-specified data collection sheet. Disagreements were resolved by discussion. The following data were extracted: type and design of the study, first authorship, country of origin, year of publication, number of patients, demographics, severity of hypothyroidism, type of intervention if relevant, time of post-intervention follow-up, and outcome parameters. The ‘Cochrane risk of bias tool’ was used to assess the risk of bias in each of the included articles (16).

113

114 **Results**

115 We identified 1690 relevant titles from PubMed and EMBASE and nine from the
116 reference lists of included papers (Figure 1). We excluded 1672 titles, after review of titles and
117 abstracts, leaving twenty-eight for full text evaluation. Six full text papers failed to meet the
118 inclusion criteria resulting in twenty-two papers for the final analyses. No randomized double blind
119 placebo controlled studies were identified.

120 Applying the ‘Cochrane Risk of Bias tool’ across studies, we found a considerable
121 risk of bias as many studies failed to describe inclusion procedures, include control groups,
122 randomize for treatment, blind observers or participants, or failed to report data previously
123 described in the method section (Table 1). As a consequence, we made no attempt to perform a
124 meta-analysis.

125 Most of the included studies (Table 2) were small, with fifty or fewer individuals in
126 thirteen of the twenty-two studies. Sixteen studies included overt hypothyroid patients only, and
127 four studies included subclinical hypothyroid patients only. The two remaining studies included
128 both groups of hypothyroid patients. There were thirteen intervention studies, eight prospective
129 observational studies, and one retrospective observational study.

130

131 **INSERT FIGURE 1, TABLE 1 AND TABLE 2 AROUND HERE**

132

133 **Respiratory symptoms and ventilation**

134 We identified six studies addressing the effect of overt or subclinical hypothyroidism
135 on respiratory symptoms and ventilation. Four of the six studies had substantial risk of bias in their
136 study design (Table 1), defined as using neither randomization, nor allocation concealment or

137 blinding. Among 124 (17) and 20 (18) patients with overt hypothyroidism, two observational
138 studies with severe risk of bias (Table 1) found increased respiratory symptoms, including shortness
139 of breath, sputum production, cough, wheezing, and airway hyper-responsiveness, with an odds
140 ratio of 2.7-3.5, when compared to 1346 healthy controls.

141 It has been debated whether pleural effusion, due to overt hypothyroidism, causes
142 some of the respiratory symptoms in patients with thyroid failure. A single study with high risk of
143 bias (Table 1) found that the effusions in such patients were primarily due to other diseases than
144 hypothyroidism (19).

145 A study of overt hypothyroid patients found that the response to hypercapnia and
146 hypoxia was reduced initially, improved seven days after either triiodothyronine (LT3) or
147 levothyroxine (LT4) treatment, and normalized in most patients after 12-24 weeks of LT4 treatment
148 only (20). That study, however, was hampered by 25% of the patients being lost to follow-up.
149 Another study failed to reproduce these results (21), may be due to a sample size half of that used in
150 the previous study. In a non-blinded study, including patients with overt or subclinical
151 hypothyroidism, the end-tidal CO₂ was reduced (22). This finding is surprising, but most likely
152 explained by hyperventilation at the time of examination.

153 Based on these data, no clear conclusions can be made regarding the impact of
154 hypothyroidism on respiratory symptoms and ventilation. The included studies all use different
155 assessment techniques, and are hampered by substantial risk of bias. We therefore refrain from
156 giving any conclusions on this topic. Only two studies have addressed the effects of LT4
157 substitution on ventilation (20, 21). Both studies suffer from a high risk of observer bias, and they
158 present opposing results, which renders a conclusion impossible (Table 3).

159

160 **Pulmonary function**

161 The results from the eleven studies addressing the influence of overt or subclinical
162 hypothyroidism on pulmonary function are contradictory. Nine of the eleven studies have study
163 designs with considerable risk of bias (Table 1). Three studies addressed the impact of overt
164 hypothyroidism on the diaphragmatic and abdominal muscle strength, and offer contradictory
165 results (21, 23, 24). Two studies, one with 43 patients (23) and another with 24 patients (24), found
166 that the diaphragmatic muscle strength improved by either LT4 or LT3 treatment. A third study,
167 including 20 patients, found no improvement after LT4 treatment (21). All three studies included a
168 limited number of participants and can therefore not be the foundation of strong conclusions (21,
169 23, 24).

170 In subclinical hypothyroidism, a single study found a reduced diaphragmatic
171 inspiratory and expiratory strength, but the results were invalidated by 3.7 times more men being
172 included in the control group than in the study group (25). As for the diaphragmatic inspiratory
173 strength, no change in this parameter has been demonstrated in this group of patients (26).

174 Two studies comprising 267 (25) and 120 patients (27) suffering from subclinical
175 hypothyroidism, found the Forced Vital Capacity (FVC) reduced by more than 250 ml, and the
176 Forced Expiratory Volume in 1 second (FEV₁) reduced by 190 ml, as compared with healthy
177 participants. A study of 20 overt hypothyroid patients showed similar findings compared to healthy
178 participants (28). Although the results may seem unequivocal, they should be interpreted with
179 caution, as the study and control groups were not comparable with respect to sex, age, and BMI.

180 Apart from these three reports, the majority of studies showed no impact of thyroid
181 dysfunction on pulmonary function when using pulmonary function tests (18, 24, 29-31), most
182 likely because of small sample sizes (21-45 patients). The lack of a control group - with a few
183 exceptions (18, 24, 30) - is clearly another limitation of these studies. One study, with 43 overt
184 hypothyroid patients (23), found that the pulmonary function improved after initiation of LT4,

185 despite the fact that it was not affected at baseline. Other studies with fewer patients could not
186 reproduce this finding (24, 29-31), which might be due to limited power.

187 As the majority of the studies have serious methodological limitations, it is difficult, if
188 not impossible, to make any clear conclusions regarding the impact of hypothyroidism, or the effect
189 of LT4 therapy, on the diaphragmatic muscle strength and pulmonary function (Table 3).

190

191 **Obstructive sleep apnea syndrome**

192 We identified seven studies which investigated the impact of overt or subclinical
193 hypothyroidism on obstructive sleep apnea syndrome (OSAS). Three of the seven studies carried a
194 significant risk of bias. Comparison across studies is difficult as study designs, populations, and the
195 employed techniques varied.

196 Nocturnal breathing abnormalities, such as restless sleep, snoring, choking, and in
197 severe cases apnea periods, occurred among 25-50% of patients with overt hypothyroidism (32-35).
198 One study found that 30% of patients with recently diagnosed primary overt hypothyroidism
199 suffered from OSAS, according to well defined criteria (34). In these patients, OSAS was reversed
200 by LT4 treatment (34). The other studies were limited by differences in BMI between control and
201 patient groups, presence of goiter, small patient numbers, or missing data on thyroid hormone
202 levels. After LT4 replacement therapy, all interventional studies demonstrated a significant
203 reduction in apnea periods, oxygen desaturation events, and in snoring and choking (33-37). In
204 subclinical hypothyroidism, one study from a specialized sleep clinic (38) found that 53% of the
205 patients had OSAS. However, a similar high rate of OSAS was found among euthyroid subjects,
206 probably reflecting selection bias in that study.

207 We conclude that overt hypothyroidism seems to be linked to sleep apnea syndrome,
208 with improvement after LT4 substitution, as shown in four of six studies (Table 3). The evidence of

209 subclinical hypothyroidism being linked with sleep apnea syndrome is vaguer as only one study
210 with serious methodological limitations addressed this issue.

211

212 **INSERT TABLE 3 AROUND HERE**

213

214 **Discussion**

215 We undertook a systematic review with the aim of elucidating the type and magnitude
216 of respiratory problems among patients with hypothyroidism and, if possible, to identify the
217 underlying physiological mechanisms. Unfortunately, many of the studies, on which we base this
218 review, are hampered by considerable heterogeneity, generally low participant numbers, and high
219 risk of observer and selection bias. We gave most credence to the studies with the least bias and
220 weighted these highest in our conclusions, which, however, still are rather vague.

221

222 **Overt and subclinical hypothyroidism**

223 Overt hypothyroidism may be associated with an increased risk of respiratory
224 symptoms (19). Such patients may also have a decreased control of breathing in response to
225 hypercapnia and hypoxia (20), diminished diaphragmatic muscle strength (23, 24), and higher
226 propensity to develop sleep apnea (34). These statements are, however, associated with great
227 uncertainty as the evidence is sparse. Additionally, the few studies, conducted within this area, are
228 hampered by considerable observer and selection bias as they rarely use blinding or randomization
229 in their designs.

230 In case of subclinical hypothyroidism, patients may have reduced diaphragmatic
231 muscle strength and lower FVC and FEV₁, according to two studies (25, 27), but these results
232 should be interpreted with caution since the male/female ratio was higher in the control groups.

233 Whether patients with subclinical hypothyroidism suffer from unrecognized sleep apnea syndrome
234 is unclarified (38).

235

236 **Thyroid hormone substitution**

237 In overt hypothyroid patients, both LT3 and LT4, taken separately, improved the
238 response to hypercapnia and hypoxia as soon as seven days after initiation of treatment (20), with
239 normalization after 2-5 months of LT4 therapy only (20). The diminished diaphragmatic muscle
240 strength normalized within three months of LT4 or LT3 treatment, in both subclinical and overt
241 hypothyroid patients (23-25). As the evidence of an effect of hypothyroidism on the pulmonary
242 function is too weak to make a conclusion, the evidence of a direct effect of LT3 or LT4
243 substitution likewise becomes inadequate to allow any conclusion on this topic (24, 29-31).

244 In hypothyroid patients with sleep apnea, most studies demonstrate an effect of LT4
245 therapy in reducing or even eliminating nocturnal apnea periods (33-37).

246 No studies have investigated the treatment effects of LT3 compared to LT4 on
247 respiratory symptoms, ventilation, pulmonary function, diaphragmatic function, or sleep apnea.

248

249 **Upper airway obstruction and hypothyroidism**

250 When hypothyroidism is caused by Hashimoto's thyroiditis, the effect of LT4
251 treatment can in part be explained by the reduction in thyroid size following restoration of
252 euthyroidism (39, 40). UAO does not always lead to subjective symptoms and may therefore be
253 overlooked in patients with thyroid disease (41). However, while thoroughly studied in nontoxic
254 goiter (12), there are no studies on the pulmonary effect following goiter reduction in Hashimoto's
255 thyroiditis.

256 The majority of Hashimoto's thyroiditis patients do not have a goiter. However, when
257 present, a goiter can cause UAO by tracheal compression, as seen in 14-31% of patients referred for

258 evaluation of simple goiter (41, 42), and in 26-60% of patients referred to thyroidectomy (43-45).
259 UAO, due to dislocation of the trachea or decrease of tracheal cross-sectional area, can have a
260 pronounced effect on the airflow (41, 42, 46), which is significantly improved by goiter volume
261 reduction (47, 48). Tracheal compression is somewhat more frequent when the goiter has a
262 substernal location (35-73%), compared to a cervical location (9-58%) (49-53). Tracheal
263 compression might not lead to symptoms, but is nevertheless a relevant consideration, as UAO may
264 develop into life-threatening respiratory insufficiency (41, 54-56). The extent to which these factors
265 are at play in hypothyroid individuals is unknown.

266

267 **Hypothyroidism and respiration in experimental animal models**

268 Based on studies in experimental animal models, the brain stem, peripheral
269 chemosensors, ATP generating enzymes, and muscle function, seem to be affected by
270 hypothyroidism. Studies in hamsters - as in man (20) - have identified a decreased response
271 (breathing frequency) to hypoxia and hypercapnia three months after development of
272 hypothyroidism (57-59). This is caused by diminished dopamine receptor (D1) protein levels in the
273 respiratory centers of the brain stem (paraventricular nucleus of the hypothalamus [PVN] and
274 solitary nucleus), and the carotid glomus (57). Dopamine receptor (D2) levels are increased in the
275 striatum and carotid glomus in the hypothyroid state, contrasting with the reduction of these
276 receptor levels in the PVN (58).

277 A reduced diaphragmatic muscle strength - as seen in some human studies (23-25) -
278 may be explained by studies in thyroidectomized rats (60). Here, a decreased capacity for energy
279 transduction and glycolysis due to diminished enzyme levels (succinate dehydrogenase, hexokinase,
280 3-hydroxyl-CoA dehydrogenase, and phosphofructokinase) in the thoracic diaphragm has been found
281 (60). Another study analyzing diaphragmatic muscle fibers from propylthiouracil-induced

282 hypothyroidism in rats showed a decreased maximum force and myosin heavy chain_{2B/2X} content
283 (61).

284 From the aforementioned, there are many pathways to the diminished respiratory
285 function, but it is clear that much remains to be explored in order to clarify how transient or
286 permanent hypothyroidism, as well as LT4 treatment, affect the respiratory system.

287

288 **Limitations**

289 In our search for evidence of the impact of hypothyroidism on respiratory function, we
290 encountered a paucity of high-quality data. No randomized controlled studies were conducted either
291 in subclinical disease or in overt hypothyroidism in combination with medical treatment. Also many
292 studies have a skewed balance between males and females, probably just reflecting the female
293 preponderance of this disorder. Nevertheless, this, as well as the small study populations, questions
294 whether the findings can be generalized to a broader population of hypothyroid individuals.
295 Furthermore, many of the older studies do not address the potential confounding effect of the co-
296 existence of goiter, if present.

297 We have not included patients with pre-existing pulmonary disease. Therefore, we
298 cannot dissect whether hypothyroidism merely adds to the severity of pre-existing pulmonary
299 disease or is the cause of *de novo* respiratory disease. There is some evidence that especially
300 autoimmune hypothyroidism may be related to pulmonary diseases such as asthma and chronic
301 obstructive pulmonary disease, but this area is sparsely investigated (62, 63).

302 As hypothyroidism affects multiple organ systems, the distinction between a primary
303 pulmonary effect and an effect mediated via the nervous system, the cardiopulmonary system or the
304 skeletal muscles is far from clear-cut. We did not include any data on cardiovascular or muscle
305 function in our analyses, which might limit the generalizability of our findings. The impact of

306 hypothyroidism on exercise capacity has been covered in a recent systematic review by Lankhaar et
307 al. (64), who identified multiple causes of exercise intolerance due to disturbances in the
308 cardiovascular-, cardiopulmonary-, musculoskeletal-, neuromuscular-, and cellular metabolic
309 systems (64). Persisting complaints of exercise intolerance was found in a subgroup of subclinical
310 hypothyroid patients not responding with symptom relief, despite adequate treatment with LT4 (64).

311

312 **Implications for the future**

313 Regarding the impact of overt hypothyroidism on respiratory symptoms, ventilation,
314 and diaphragmatic muscle strength, no conclusions can be provided due to the small number of
315 studies and the significant methodological weaknesses. Thus, this area of research is open for
316 retesting hypotheses regarding the effects of hypothyroidism on various features of the respiratory
317 system, employing prospective study designs, validated methods, and blinded assessments. The
318 influence of overt hypothyroidism on the diaphragmatic function should also be further explored,
319 since this unique thoraco-abdominal muscle has an important role in forming the voice, cough, and
320 for exercise capacity. As for subclinical hypothyroidism, it remains uncertain whether the ventilator
321 response to hypoxia and hypercapnia is affected, or whether these patients are more prone to suffer
322 from sleep apnea syndrome than the background population.

323 Importantly, as most patients diagnosed with hypothyroidism are substituted with
324 LT4, data on the long-term impact of persistent hypothyroidism on the respiratory function is
325 virtually non-existent.

326

327 **Conclusions**

328 The evidence of an impact of hypothyroidism on respiratory function is at best limited. We
329 found no information linking the effect of hypothyroidism on respiratory function to the increased

330 mortality from pulmonary diseases, as reported previously from registry-based data (8). In contrast
331 to the considerable knowledge regarding the influence of hypothyroidism on the cardiovascular
332 system (65, 66), many aspects of the influence on the respiratory function have been inadequately
333 addressed or not explored at all.

334

335

336

337 **Author Disclosure Statement**

338 There are no conflicts of interest in this study

339

340 **Corresponding author**

341 Jesper Roed Sorensen, MD

342 Department of ORL - Head & Neck Surgery

343 Odense University Hospital

344 Sdr. Boulevard 29, 5000 Odense C, Denmark

345 E-mail: jesper.roed.sorensen@rsyd.dk. Phone: +45 65 41 28 10. Fax: +45 66 19 26 15

346

347

Reference list

1. Canaris GJ, Manowitz NR, Mayor G, Ridgway EC 2000 The Colorado thyroid disease prevalence study. *Arch Intern Med* 160:526-534.
2. Biondi B 2012 Natural history, diagnosis and management of subclinical thyroid dysfunction. *Best Pract Res Clin Endocrinol Metab* 26:431-446.
3. Vaidya B, Pearce SH 2008 Management of hypothyroidism in adults. *BMJ* 337:a801.
4. Carle A, Laurberg P, Pedersen IB, Knudsen N, Perrild H, Ovesen L, Rasmussen LB, Jorgensen T 2006 Epidemiology of subtypes of hypothyroidism in Denmark. *Eur J Endocrinol* 154:21-28.
5. Bonnema SJ, Hegedus L 2012 Radioiodine therapy in benign thyroid diseases: effects, side effects, and factors affecting therapeutic outcome. *Endocr Rev* 33:920-980.
6. Watt T, Hegedus L, Rasmussen AK, Groenvold M, Bonnema SJ, Bjorner JB, Feldt-Rasmussen U 2007 Which domains of thyroid-related quality of life are most relevant? Patients and clinicians provide complementary perspectives. *Thyroid* 17:647-654.
7. Nexø MA, Watt T, Cleal B, Hegedus L, Bonnema SJ, Rasmussen AK, Feldt-Rasmussen U, Bjorner JB 2015 Exploring the experiences of people with hypo- and hyperthyroidism. *Qual Health Res* 25:945-953.
8. Thvilum M, Brandt F, Almind D, Christensen K, Hegedus L, Brix TH 2013 Excess mortality in patients diagnosed with hypothyroidism: a nationwide cohort study of singletons and twins. *J Clin Endocrinol Metab* 98:1069-1075.
9. Thvilum M, Brandt F, Almind D, Christensen K, Brix TH, Hegedus L 2013 Type and extent of somatic morbidity before and after the diagnosis of hypothyroidism. a nationwide register study. *PLoS One* 8:e75789.
10. Zwillich CW, Pierson DJ, Hofeldt FD, Lufkin EG, Weil JV 1975 Ventilatory control in myxedema and hypothyroidism. *N Engl J Med* 292:662-665.
11. Salomo LH, Laursen AH, Reiter N, Feldt-Rasmussen U 2014 Myxoedema coma: an almost forgotten, yet still existing cause of multiorgan failure. *BMJ Case Rep* 2014.
12. Sorensen JR, Hegedus L, Kruse-Andersen S, Godballe C, Bonnema SJ 2014 The impact of goitre and its treatment on the trachea, airflow, oesophagus and swallowing function. A systematic review. *Best Pract Res Clin Endocrinol Metab* 28:481-494.
13. Dudhia SB, Dudhia BB 2014 Undetected hypothyroidism: A rare dental diagnosis. *J Oral Maxillofac Pathol* 18:315-319.
14. Moher D, Liberati A, Tetzlaff J, Altman DG, Group P 2009 Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *BMJ* 339:b2535.
15. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D 2009 The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. *BMJ* 339:b2700.
16. Green JPHS 2011 *Cochrane Handbook for Systematic Reviews of Interventions*. The cochrane collaboration.
17. Birring SS, Morgan AJ, Prudon B, McKeever TM, Lewis SA, Falconer Smith JF, Robinson RJ, Britton JR, Pavord ID 2003 Respiratory symptoms in patients with treated hypothyroidism and inflammatory bowel disease. *Thorax* 58:533-536.
18. Birring SS, Patel RB, Parker D, McKenna S, Hargadon B, Monteiro WR, Falconer Smith JF, Pavord ID 2005 Airway function and markers of airway inflammation in patients with treated hypothyroidism. *Thorax* 60:249-253.

- 395 **19.** Gottehrer A, Roa J, Stanford GG, Chernow B, Sahn SA 1990 Hypothyroidism and pleural
396 effusions. *Chest* 98:1130-1132.
- 397 **20.** Ladenson PW, Goldenheim PD, Ridgway EC 1988 Prediction and reversal of blunted
398 ventilatory responsiveness in patients with hypothyroidism. *Am J Med* 84:877-883.
- 399 **21.** Duranti R, Gheri RG, Gorini M, Gigliotti F, Spinelli A, Fanelli A, Scano G 1993 Control of
400 breathing in patients with severe hypothyroidism. *Am J Med* 95:29-37.
- 401 **22.** Ansarin K, Niroomand B, Najafipour F, Aghamohammadzadeh N, Niafar M, Sharifi A,
402 Shoja MM 2011 End-tidal CO(2) levels lower in subclinical and overt hypothyroidism than
403 healthy controls; no relationship to thyroid function tests. *Int J Gen Med* 4:29-33.
- 404 **23.** Siafakas NM, Salesiotou V, Filaditaki V, Tzanakis N, Thalassinou N, Bouros D 1992
405 Respiratory muscle strength in hypothyroidism. *Chest* 102:189-194.
- 406 **24.** Gorini M, Spinelli A, Cangioli C, Gigliotti F, Duranti R, Arcangeli P, Scano G 1989 Control
407 of breathing in patients with short-term primary hypothyroidism. *Lung* 167:43-53.
- 408 **25.** Cakmak G, Saler T, Saglam ZA, Yenigun M, Ataoglu E, Demir T, Temiz LU 2011
409 Pulmonary functions in patients with subclinical hypothyroidism. *J Pak Med Assoc* 61:951-
410 953.
- 411 **26.** Reuters VS, Teixeira Pde F, Vigario PS, Almeida CP, Buescu A, Ferreira MM, de Castro
412 CL, Gold J, Vaisman M 2009 Functional capacity and muscular abnormalities in subclinical
413 hypothyroidism. *Am J Med Sci* 338:259-263.
- 414 **27.** Cakmak G, Saler T, Saglam ZA, Yenigun M, Demir T 2007 Spirometry in patients with
415 clinical and subclinical hypothyroidism. *Tuberk Toraks* 55:266-270.
- 416 **28.** Swami G, Singh S, Singh KP, Gupta M 2010 Effect of yoga on pulmonary function tests of
417 hypothyroid patients. *Indian J Physiol Pharmacol* 54:51-56.
- 418 **29.** Wilson WR, Bedell GN 1960 The pulmonary abnormalities in myxedema. *J Clin Invest*
419 39:42-55.
- 420 **30.** Ambrosino N, Pacini F, Paggiaro PL, Martino E, Contini V, Turini L, Tarchi M, Vitti P,
421 Bramanti M, Pinchera A 1985 Impaired ventilatory drive in short-term primary
422 hypothyroidism and its reversal by L-triiodothyronine. *J Endocrinol Invest* 8:533-536.
- 423 **31.** Koral L, Hekimsoy Z, Yildirim C, Ozmen B, Yorgancioglu A, Girgin A 2006 Does thyroid
424 replacement therapy affect pulmonary function tests in patients with subclinical
425 hypothyroidism? *Saudi Med J* 27:329-332.
- 426 **32.** Pelttari L, Rauhala E, Polo O, Hyyppa MT, Kronholm E, Viikari J, Kantola I 1994 Upper
427 airway obstruction in hypothyroidism. *J Intern Med* 236:177-181.
- 428 **33.** Lin CC, Tsan KW, Chen PJ 1992 The relationship between sleep apnea syndrome and
429 hypothyroidism. *Chest* 102:1663-1667.
- 430 **34.** Jha A, Sharma SK, Tandon N, Lakshmy R, Kadiravan T, Handa KK, Gupta R, Pandey
431 RM, Chaturvedi PK 2006 Thyroxine replacement therapy reverses sleep-disordered
432 breathing in patients with primary hypothyroidism. *Sleep Med* 7:55-61.
- 433 **35.** Hira HS, Sibal L 1999 Sleep apnea syndrome among patients with hypothyroidism. *J Assoc*
434 *Physicians India* 47:615-618.
- 435 **36.** Misiolek M, Marek B, Namyslowski G, Scierski W, Zwirska-Korczala K, Kazmierczak-
436 Zagorska Z, Kajdaniuk D, Misiolek H 2007 Sleep apnea syndrome and snoring in patients
437 with hypothyroidism with relation to overweight. *J Physiol Pharmacol* 58 Suppl 1:77-85.
- 438 **37.** Rajagopal KR, Abbrecht PH, Derderian SS, Pickett C, Hofeldt F, Tellis CJ, Zwillich CW
439 1984 Obstructive sleep apnea in hypothyroidism. *Ann Intern Med* 101:491-494.
- 440 **38.** Resta O, Carratu P, Carpagnano GE, Maniscalco M, Di Gioia G, Lacedonia D, Giorgino R,
441 De Pergola G 2005 Influence of subclinical hypothyroidism and T4 treatment on the

prevalence and severity of obstructive sleep apnoea syndrome (OSAS). *J Endocrinol Invest* 28:893-898.

39. Caturegli P, De Remigis A, Rose NR 2014 Hashimoto thyroiditis: clinical and diagnostic criteria. *Autoimmun Rev* 13:391-397.
40. Hegedus L, Hansen JM, Feldt-Rasmussen U, Hansen BM, Hoier-Madsen M 1991 Influence of thyroxine treatment on thyroid size and anti-thyroid peroxidase antibodies in Hashimoto's thyroiditis. *Clin Endocrinol (Oxf)* 35:235-238.
41. Menon SK, Jagtap VS, Sarathi V, Lila AR, Bandgar TR, Menon PS, Shah NS 2011 Prevalence of upper airway obstruction in patients with apparently asymptomatic euthyroid multi nodular goitre. *Indian J Endocrinol Metab* 15:S127-131.
42. Miller MR, Crapo R, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, Enright P, van der Grinten CP, Gustafsson P, Jensen R, Johnson DC, MacIntyre N, McKay R, Navajas D, Pedersen OF, Pellegrino R, Viegi G, Wanger J, Force AET 2005 General considerations for lung function testing. *Eur Respir J* 26:153-161.
43. Thusoo TK, Gupta U, Kochhar K, Hira HS 2000 Upper airway obstruction in patients with goiter studies by flow volume loops and effect of thyroidectomy. *World J Surg* 24:1570-1572.
44. Jauregui R, Lilker ES, Bayley A 1977 Upper airway obstruction in euthyroid goiter. *JAMA* 238:2163-2166.
45. Albareda M, Viguera J, Santiveri C, Lozano P, Mestron A, Bengoa N, Calvet R, Roger A, Pardillo D, Delgado E, Vila L 2010 Upper airway obstruction in patients with endotracheal goiter enlargement: no relationship between flow-volume loops and radiological tests. *Eur J Endocrinol* 163:665-669.
46. Torchio R, Gulotta C, Perboni A, Ciacco C, Guglielmo M, Orlandi F, Milic-Emili J 2003 Orthopnea and tidal expiratory flow limitation in patients with euthyroid goiter. *Chest* 124:133-140.
47. Bonnema SJ, Bertelsen H, Mortensen J, Andersen PB, Knudsen DU, Bastholt L, Hegedus L 1999 The feasibility of high dose iodine 131 treatment as an alternative to surgery in patients with a very large goiter: effect on thyroid function and size and pulmonary function. *J Clin Endocr Metab* 84:3636-3641.
48. Bonnema SJ, Nielsen VE, Boel-Jorgensen H, Grupe P, Andersen PB, Bastholt L, Hegedus L 2008 Recombinant human thyrotropin-stimulated radioiodine therapy of large nodular goiters facilitates tracheal decompression and improves inspiration. *J Clin Endocr Metab* 93:3981-3984.
49. Nettekville JL, Coleman SC, Smith JC, Smith MM, Day TA, Burkey BB 1998 Management of substernal goiter. *Laryngoscope* 108:1611-1617.
50. Cooper JC, Nakielnny R, Talbot CH 1991 The use of computed tomography in the evaluation of large multinodular goitres. *Ann R Coll Surg Engl* 73:32-35.
51. Shen WT, Kebebew E, Duh QY, Clark OH 2004 Predictors of airway complications after thyroidectomy for substernal goiter. *Arch Surg* 139:656-659; discussion 659-660.
52. Abboud B, Sleilaty G, Mallak N, Abou Zeid H, Tabchy B 2010 Morbidity and mortality of thyroidectomy for substernal goiter. *Head & Neck* 32:744-749.
53. Shin JJ, Grillo HC, Mathisen D, Katlic MR, Zurakowski D, Kamani D, Randolph GW 2011 The surgical management of goiter: Part I. Preoperative evaluation. *Laryngoscope* 121:60-67.
54. Wilson M, Davis TM, Bade PG, Castelden WM 1995 Tracheo-oesophageal compression due to rapid thyroid enlargement after radioiodine treatment. *MJA* 162:485-486.

489 **55.** Ghai A, Hooda S, Wadherra R, Garg N 2011 Gross tracheal deviation: airway challenges
490 and concerns--two case reports. *Acta Anaesthesiol Belg* 62:203-206.

491 **56.** Shaha A, Alfonso A, Jaffe BM 1987 Acute airway distress due to thyroid pathology.
492 *Surgery* 102:1068-1074.

493 **57.** Schlenker EH, Schultz HD 2011 Hypothyroidism attenuates SCH 23390-mediated
494 depression of breathing and decreases D1 receptor expression in carotid bodies, PVN and
495 striatum of hamsters. *Brain Res* 1401:40-51.

496 **58.** Schlenker EH, Schultz HD 2012 Hypothyroidism stimulates D2 receptor-mediated breathing
497 in response to acute hypoxia and alters D2 receptors levels in carotid bodies and brain.
498 *Respir Physiol Neurobiol* 180:69-78.

499 **59.** Sykora C, Amor M, Schlenker E 2013 Age and hypothyroidism affect dopamine modulation
500 of breathing and D(2) receptor levels. *Respir Physiol Neurobiol* 185:257-264.

501 **60.** Ianuzzo CD, Chen V, O'Brien P, Keens TG 1984 Effect of experimental dysthyroidism on
502 the enzymatic character of the diaphragm. *J Appl Physiol Respir Environ Exerc Physiol*
503 56:117-121.

504 **61.** Geiger PC, Cody MJ, Han YS, Hunter LW, Zhan WZ, Sieck GC 2002 Effects of
505 hypothyroidism on maximum specific force in rat diaphragm muscle fibers. *J Appl Physiol*
506 (1985) 92:1506-1514.

507 **62.** Birring SS, Brightling CE, Symon FA, Barlow SG, Wardlaw AJ, Pavord ID 2003 Idiopathic
508 chronic cough: association with organ specific autoimmune disease and bronchoalveolar
509 lymphocytosis. *Thorax* 58:1066-1070.

510 **63.** Birring SS, Brightling CE, Bradding P, Entwisle JJ, Vara DD, Grigg J, Wardlaw AJ, Pavord
511 ID 2002 Clinical, radiologic, and induced sputum features of chronic obstructive pulmonary
512 disease in nonsmokers: a descriptive study. *Am J Respir Crit Care Med* 166:1078-1083.

513 **64.** Lankhaar JA, de Vries WR, Jansen JA, Zelissen PM, Backx FJ 2014 Impact of overt and
514 subclinical hypothyroidism on exercise tolerance: a systematic review. *Res Q Exerc Sport*
515 85:365-389.

516 **65.** Grais IM, Sowers JR 2014 Thyroid and the heart. *Am J Med* 127:691-698.

517 **66.** Biondi B 2012 Mechanisms in endocrinology: Heart failure and thyroid dysfunction. *Eur J*
518 *Endocrinol* 167:609-618.

519

520




Table 1:

Risk of bias summary in the 22 studies included for review. Unclear risk of bias (?), low risk of bias (+), and high risk of bias (-).

Study	Random sequence generation	Allocation concealment	Blinding of participants and personnel	Blinding of outcome assessment	Incomplete data	Selective reporting	Other bias
Birring 2003 (17)	+	?	?	?	+	?	+
Birring 2005 (18)	+	?	+	+	+	?	+
Gottehrer 1990 (19)	?	?	?	?	+	?	+
Ladenson 1988 (20)	?	?	?	?	+	?	+
Duranti 1993 (21)	?	?	?	?	+	-	?
Ansarin 2011 (22)	?	?	?	?	+	?	+
Siafakas 1992 (23)	?	?	?	?	+	?	+
Gorini 1989 (24)	?	?	?	?	-	?	?
Cakmak 2011 (25)	-	?	?	?	+	?	-
Reuters 2009 (26)	?	?	+	+	+	?	+
Cakmak 2007 (27)	?	?	?	?	-	?	+
Swami 2010 (28)	?	?	?	?	+	?	-
Wilson 1960 (29)	-	?	?	?	+	?	?
Ambrosino 1985 (30)	?	?	?	?	-	?	+
Koral 2006 (31)	?	?	?	?	+	?	-
Pelttari 1994 (32)	?	?	+	+	+	?	-
Lin 1992 (33)	?	?	+	+	+	?	?
Jha 2006 (34)	?	?	+	+	+	?	+
Hira1999 (35)	?	?	+	+	-	?	+
Misiolek 2007 (36)	?	?	?	?	-	?	-
Rajagopal 1984 (37)	?	?	?	?	-	?	-
Resta 2005 (38)	?	?	?	?	+	?	-

Table 2:

Included studies regarding the respiratory manifestations of hypothyroidism. Observational (OB), Interventional (IN), Retrospective (RE), Overt hypothyroidism (HT), Subclinical hypothyroidism (sHT), Thyrotropin (TSH), Levothyroxine (LT4), Triiodothyronine (LT3) Questionnaire (Quest), Carbon dioxide measurements (CO₂), Carbon monoxide (CO), Manovacumeter (MVM), Pulmonary function test (PFT), Forced Vital Capacity (FVC), Forced Expiratory volume 1 second (FEV₁), Polysomnography (PSG), Obstructive sleep apnea (OSAS), Apnea Hypopnea Index (AHI) and Respiratory Disturbance Index (RDI). Age: mean (years). TSH is given as the mean value (mIU/l) at time of diagnosis. Non-available: NA

Study	Design	<i>n</i>	Age	Cohort	Methods	Results
Birring 2003 (17)	OB	1534	56	HT (primary), TSH: NA	Quest	Breathlessness, sputum and cough more prevalent.
Birring 2005 (18)	IN	45	52	HT (primary), TSH 2	PFT	No change in PFT. Increase in respiratory symptoms.
Gottehrer 1990 (19)	RE	128	NA	HT (primary), TSH: NA	X-ray	Pleural effusions rarely caused by hypothyroidism.
Ladenson 1988 (20)	IN	38	50	HT (primary), TSH: 97	MVM	Depressed response to hypoxia and hypercapnia. Improved within one week of LT3 or LT4 treatment in 75 % of patients. Normalized after LT4 for 12-24 weeks.
Duranti 1993 (21)	IN	20	54	HT (primary), TSH > 64	MVM, PFT	No change in ventilator control systems or diaphragmatic strength after LT4.
Ansarin 2011 (22)	OB	95	35	sHT/HT (NA), TSH: 8/44	CO ₂	Reduced alveolar ventilation or hypoventilation in both groups.
Siafakas 1992 (23)	IN	43	54	HT (various causes), TSH: 55	MVM PFT	Diaphragmatic in- and expiratory strength, FVC and FEV ₁ improved after LT4.
Gorini 1989 (24)	IN	24	42	HT (surgery), TSH: 44	PFT	No change in PFT. FVC and P _i Max improved after LT3.
Cakmak 2011 (25)	OB	184	46	sHT (NA), TSH: 11	PFT	Reduced diaphragmatic strength, FVC and FEV ₁ .
Reuters 2009 (26)	OB	68	47	sHT (various causes), TSH: 5	MVM	No difference in inspiratory strength.
Cakmak 2007 (27)	OB	267	43	sHT/HT (NA), TSH: 10/74	PFT	Reduced FVC and FEV ₁ .
Swami 2010 (28)	IN	40	40	HT (NA), TSH: 14	PFT	Reduced FVC and FEV ₁ .
Wilson 1960 (29)	IN	26	51	HT (NA), TSH: NA	PFT	No effect of LT3/desiccated thyroid on PFT.
Ambrosino 1985 (30)	IN	21	37	HT (surgery), TSH: 51	PFT	No change in PFT and no effect of LT3.
Koral 2006 (31)	IN	38	43	sHT (NA), TSH: 13	PFT	No effect of LT4 on PFT.
Peltari 1994 (32)	OB	214	43	HT (NA), TSH > 10	PSG	50 % had nocturnal breathing abnormalities.
Lin 1992 (33)	IN	85	46	HT (NA), TSH > 25	PSG	25 % had mild to severe OSAS. Improved after LT4.
Jha 2006 (34)	IN	50	34	HT (primary), TSH: 100	PSG	30 % had AHI > 5. Reversible after LT4.
Hira1999 (35)	IN	20	33	HT (NA), TSH: NA	PSG	45 % had OSAS. Majority resolved after LT4.
Misiolek 2007 (36)	IN	15	50	HT (NA), TSH: 39	RDI	No change in RDI, but reduced sleepiness and snoring after LT4.
Rajagopal 1984 (37)	IN	9	49	HT (NA), TSH: NA	PSG	Reduced number of apneas after LT4.
Resta 2005 (38)	OB	108	52	sHT (NA), TSH: 8	PSG	53 % of patients had OSAS, which ameliorated after treatment.

Table 3:

Recommendations based on strength of evidence. Moderate level of evidence: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. Low level of evidence: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.

Levothyroxine (LT4), Forced Vital Capacity (FVC) and Forced Expiratory volume 1 second (FEV₁).

Theme	Physiological effect	Level of evidence	Sources
Ventilation in hypothyroid patients	Affected ventilation	Low (one or more studies with severe limitations)	(20-22)
	Ventilation normalizes after LT4 treatment	Low (one or more studies with severe limitations)	
Diaphragmatic muscle strength in hypothyroid patients	Reduced diaphragmatic muscle strength	Low (one or more studies with severe limitations)	(21, 23-26)
	Diaphragmatic muscle strength increases after LT4 treatment	Low (one or more studies with severe limitations)	
Pulmonary function tests in hypothyroid patients	No change in FVC and FEV ₁	Low (one or more studies with severe limitations)	(18, 23-24, 25, 27-31)
	Increased FVC and FEV ₁ after LT4 treatment	Low (one or more studies with severe limitations)	
Sleep apnea in hypothyroid patients	Nocturnal breathing abnormalities due to upper airway obstruction	Moderate (several studies with some limitations)	(32-38)
	Nocturnal breathing abnormalities reverses after LT4 treatment	Moderate (several studies with some limitations)	